TScan Therapeutics (TCRX) Enterprise Value (2020 - 2025)
Historic Enterprise Value for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to -$184.5 million.
- TScan Therapeutics' Enterprise Value rose 3196.63% to -$184.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$184.5 million, marking a year-over-year increase of 3196.63%. This contributed to the annual value of -$290.1 million for FY2024, which is 5106.43% down from last year.
- Latest data reveals that TScan Therapeutics reported Enterprise Value of -$184.5 million as of Q3 2025, which was up 3196.63% from -$218.0 million recorded in Q2 2025.
- In the past 5 years, TScan Therapeutics' Enterprise Value registered a high of -$95.6 million during Q1 2023, and its lowest value of -$297.7 million during Q2 2024.
- Moreover, its 5-year median value for Enterprise Value was -$182.3 million (2021), whereas its average is -$183.3 million.
- Per our database at Business Quant, TScan Therapeutics' Enterprise Value plummeted by 36392.75% in 2021 and then skyrocketed by 3211.49% in 2023.
- Quarter analysis of 5 years shows TScan Therapeutics' Enterprise Value stood at -$161.4 million in 2021, then rose by 25.64% to -$120.0 million in 2022, then plummeted by 60.0% to -$192.0 million in 2023, then plummeted by 51.06% to -$290.1 million in 2024, then surged by 36.42% to -$184.5 million in 2025.
- Its last three reported values are -$184.5 million in Q3 2025, -$218.0 million for Q2 2025, and -$251.7 million during Q1 2025.